JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in nonpharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the second quarter 2024 and host a corporate update conference call on Tuesday, Augu ...

About Dyadic International, Inc. According to the terms of the agreement, Dyadic will receive an upfront milestone payment of $1.5MM and have agreed to a share of profits received by PHB from the sale of animal-free recombinant albumin products produced using Dyadic's filamentous fungal microbial platforms. A portion of the upfront milestone payment will be allocated to the technology transfer and commercialization effort. The initial focus of the partnership will be the commercialization of recombinant hum ...

JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets. "Over the past few years, we have observed both increased interest and demand for alternative sources of protein for the diagnostic and life sciences industries. We are thrilled ...

公司活动 - 公司管理层将参加2024年6月的行业活动包括6月3 - 6日在加州圣地亚哥会议中心的BIO 2024 6月17 - 18日在伊利诺伊州芝加哥市中心万丽酒店的Future Food Tech - Alt Proteins 6月25 - 27日在华盛顿特区首都希尔顿酒店的2024 NIIMBL全国会议[1][2] 公司概况 - 公司是一家生物技术公司专注于高效大规模生产用于人类和动物疫苗和治疗的蛋白质以及包括食品营养和健康在内的非医药应用[1][3] - 公司的基因表达和蛋白质生产平台基于高产且可扩展的真菌嗜热毁丝霉（原名嗜热真菌）其主要技术C1 - 细胞蛋白质生产平台基于一种工业验证的微生物（名为C1）用于加速开发降低生产成本并提高生物疫苗和药物在人类和动物健康市场的灵活商业规模的性能公司还开发了Dapibus™丝状真菌微生物蛋白质生产平台用于非医药应用的低成本蛋白质代谢物和其他生物产品的快速开发和大规模制造[4] - 公司致力于使合作伙伴和合作者在发达国家和新兴国家开发有效的预防和治疗方法通过推进其专有微生物平台技术包括主要资产DYAI - 100新冠疫苗候选物以及其他生物疫苗抗体和其他生物产品建立活跃的产品线[5] 了解公司途径 - 可访问http://www.dyadic.com了解公司及其对更快更大规模和更低成本将疫苗和其他生物产品推向市场的承诺[6]

JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness, today announced that its management will be attending the following industry events during June 2024. BIO 2024 San Diego Convention Center, San Diego, CA Jun 3 – 6, 202 ...

分组1 - 公司继续建立在2023年的势头之上,并进一步加快了进展 [8][9] - 公司的C1技术和Dapibus表达平台受到学术界、行业、政府机构和非营利组织的高度认可 [9] - 公司在第一季度成功完成了600万美元的可转换票据融资,没有发行任何认股权证 [10] 分组2 - 公司在人类健康领域取得了积极的临床试验结果,引起了学术界、行业和政府的广泛关注 [11][12] - 公司与两家前十大制药公司开展了12个全额资助的疫苗和抗体项目,涵盖多个疾病领域 [12][13][14][19] - 公司与以色列生物研究所合作,利用公司的微生物平台专长和该所在抗体和抗原发现方面的能力,开发和制造治疗和预防新兴疾病以及潜在生物威胁的产品 [13] 分组3 - 公司在动物健康领域继续拓展疫苗和治疗性蛋白质,重点关注人畜共患病,如H5N1禽流感 [21][22][23][24][25] - 公司与ViroVax合作开发了一种基于C1平台的H5N1禽流感疫苗候选药物,具有良好的免疫原性 [23][24][25] - 公司与Cygnus Technologies合作开发了C1宿主细胞蛋白ELISA检测试剂盒,满足监管要求 [26] 分组4 - 公司在替代蛋白质领域保持高度兴趣,认为这一领域具有巨大的市场潜力和近期收入机会 [28][29] - 公司开发了多种重组蛋白质产品,如重组血清白蛋白、转铁蛋白和非动物乳制品,并与多家公司建立了合作关系 [30][31][32][33][34][35][36][37][38] - 公司正在开发多种工业酶,如用于生物燃料和造纸行业的纤维素酶,以拓展收入来源 [38][39] 问答环节重要的提问和回答 问题1 **John Vandermosten 提问** 公司在重组人血清白蛋白和牛血清白蛋白项目上需要完成哪些里程碑,才能实现首次销售?[52][53][54] **Joseph Hazelton 回答** 公司需要完成产能放大,并完成监管要求,预计在12个月内实现首次销售。公司将与合作伙伴共同加快这一进程。[54][55][57][59] 问题2 **John Vandermosten 提问** 公司与合作伙伴的财务结构如何,是否包括里程碑付款和特许权使用费?[55][56] **Joseph Hazelton 和 Mark Emalfarb 回答** 合作协议将包括初始里程碑付款,以及后续的特许权使用费分成。这种结构可以让双方共享增长的收益。[57][59][60][61] 问题3 **John Vandermosten 提问** 公司对DYAI-100 COVID-19疫苗候选药物的监管计划如何?[64] **Mark Emalfarb 回答** 公司不打算继续推进DYAI-100,而是将关注开发更有效、持续时间更长的新冠疫苗候选药物。公司正与FDA保持沟通,并考虑推进其他基于C1平台的疫苗,如禽流感疫苗。[65][66][67][68]

Exhibit 99.1 Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress Human Health Sector Animal Health Sector Alternative Proteins Sector Corporate JUPITER, FL / May 14, 2024 (GLOBE NEWSWIRE) Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 000-55264 DYADIC INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 45-0486747 State or ...

Human Health Sector Animal Health Sector Alternative Proteins Sector Corporate JUPITER, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the first quarter of 2024 and ...

JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that its management will be attending the following industry and investor events during t ...